SPRB

#3695
Spruce Biosciences, Inc. - Common Stock
60.7 8 USD
-0.04%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
60.78
60.78
Intervallo Annuale
7.26
240.00
Variazione giornaliera
-3.98%
Variazione Mensile
+41.32%
Variazione di 6 mesi
+12.85%
Variazione Annuale
+452.55%
Chiusura Precedente
63.3 0
Open
60.7 8
Minimo
60.7 8
Massimo
60.7 8
Volume
5
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SPRUCE BIOSCIENCES, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
SPRUCE BIOSCIENCES, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q1 FY2026
8-K

SPRUCE BIOSCIENCES, INC. current report, Q4 FY2025

Full document

Business Context and Reporting Period

Company: Spruce Biosciences, Inc. (SPRB)
Filing Type: Form 8-K (Current Report)
Date of Report: October 7, 2025
Event: Entry into a Material Definitive Agreement for a Private Placement of equity securities.

Key Financial Metrics and Transaction Details

This filing details a capital raise rather than periodic financial performance. Key transaction metrics include:

  • Total Gross Proceeds: Approximately $50.0 million.
  • Securities Issued:
    • 502,181 shares of Common Stock.
    • Pre-funded warrants to purchase up to 233,144 shares of Common Stock.
  • Purchase Price: $68.00 per share for Common Stock; $67.99 per Pre-Funded Warrant.
  • Placement Agent Fees: Approximately 6.0% of aggregate gross proceeds.
  • Expected Closing Date: On or about October 9, 2025.

Note: The filing does not provide current revenue, profit, cash flow, or debt levels. These metrics are not applicable to this specific event-driven report.

Material Changes and Outlook

Capital Structure Change: The transaction will increase the company's outstanding share count upon closing and exercise of warrants, subject to beneficial ownership limitations (9.99% or 4.99% caps).

Strategic Outlook:

  • Product Pipeline: The Company intends to advance tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).
  • Regulatory Timeline: Targeting a Biologics License Application (BLA) submission in the first quarter of 2026.
  • Commercialization: Potential U.S. commercial launch in late 2026.

Risks and Contingencies

  • Closing Conditions: The transaction is subject to customary closing conditions.
  • Registration Obligations: The Company must file a registration statement within 20 days of closing; failure to do so may result in cash penalties.
  • Forward-Looking Statements: Actual results regarding the offering, BLA submission, and commercial launch may differ materially due to market conditions and other uncertainties.

Investor Verification Checklist

  • Confirm the actual closing date and final gross proceeds received.
  • Verify the filing of the registration statement for resale of securities within the 20-day deadline post-closing.
  • Monitor progress on the TA-ERT BLA submission timeline for Q1 2026.
  • Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific penalty clauses and covenants.

Notizie